| RESEARCH ARTICLE
|Year : 2014 | Volume
| Issue : 5 | Page : 485-489
Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: A pharmacoeconomic comparison of antihypertensive efficacy of beta blockers
Rachna S Patel1, Kamal H Sharma2, Nitisha A Kamath3, Nirav H Patel1, Ankita M Thakkar1
1 Shivrath Centre of Excellence in Clinical Research, Ahmedabad, India
2 U. N. Mehta Institute of Cardiology and Research Centre, Ahmedabad, India
3 B. J. Medical College, Ahmedabad, Gujarat, India
Objective: To estimate and compare the cost-effectiveness and safety of nebivolol with sustained-release metoprolol in reducing blood pressure by 1 mm of Hg per day in hypertensive patients.
Materials and Methods: This was a prospective, randomized, open label, observational analysis of cost-effectiveness, in a questionnaire-based fashion to compare the cost of nebivolol (2.5 mg, 5 mg, 10 mg) and sustained released metoprolol succinate (25 mg, 50 mg, 100 mg) in hypertensive patients using either of the two drugs. A total of 60 newly detected drug naïve hypertensive patients were considered for the comparison, of which 30 patients were prescribed nebivolol and the other 30 were prescribed metoprolol succinate as per the recommended dosage. Based on the data, statistical analysis was carried out using GraphPad Prism 5 and MS Excel Spreadsheet 2007.
Result: The cost of reducing 1 mm of Hg blood pressure per day with nebivolol was 0.60, 0.70, and 1.06 INR, whereas that of metoprolol succinate was 0.93, 1.18, and 1.25 INR at their respective equivalent doses, hence significantly lower with the nebivolol group as compared to the metoprolol group (P < 0.05).
Conclusion: This pharmacoeconomic analysis shows that nebivolol is more cost-effective as compared to metoprolol when the cost per reduction in blood pressure per day is considered. This may affect the patients economically during their long-term use of these molecules for the treatment of hypertension.
Nitisha A Kamath
B. J. Medical College, Ahmedabad, Gujarat
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*